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Abstract
Background: The events required to initiate host defenses against invading pathogens involve complex signaling cascades
comprised of numerous adaptor molecules, kinases, and transcriptional elements, ultimately leading to the production of
proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-a). How these signaling cascades are regulated, and
the proteins and regulatory elements participating are still poorly understood.
Results: We report here the development a completely random short-hairpin RNA (shRNA) library coupled with a novel
forward genetic screening strategy to identify inhibitors of Toll-like receptor (TLR) dependent proinflammatory responses.
We developed a murine macrophage reporter cell line stably transfected with a construct expressing diphtheria toxin-A (DT-
A) under the control of the TNF-a-promoter. Stimulation of the reporter cell line with the TLR ligand lipopolysaccharide (LPS)
resulted in DT-A induced cell death, which could be prevented by the addition of an shRNA targeting the TLR adaptor
molecule MyD88. Utilizing this cell line, we screened a completely random lentiviral short hairpin RNA (shRNA) library for
sequences that inhibited TLR-mediated TNF-a production. Recovery of shRNA sequences from surviving cells led to the
identification of unique shRNA sequences that significantly inhibited TLR4-dependent TNF-a gene expression. Furthermore,
these shRNA sequences specifically blocked TLR2 but not TLR3-dependent TNF-a production.
Conclusions: Thus, we describe the generation of novel tools to facilitate large-scale forward genetic screens in mammalian
cells and the identification of potent shRNA inhibitors of TLR2 and TLR4- dependent proinflammatory responses.
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Introduction
Mammalian Toll-like receptors (TLRs) are single-spanning
membrane proteins that display a conserved cytoplasmic
Toll2interleukin 1 (IL-1) receptor (TIR) domain motif [1].
Individual TLRs recognize a distinct repertoire of conserved
microbial products and are critical mediators of the innate
immune response to infection [2]. For example, TLR4 recognizes
LPS, an integral cell wall component of Gram-negative bacteria
[3,4,5], TLR2 recognizes peptidoglycan [6,7] and bacterial
lipoproteins [8,9,10], and TLR3 recognizes double stranded
RNA (dsRNA), which is produced by many viruses during
replication [11].
As a result of shared, cytoplasmic TIR domains, all TLRs utilize
similar signaling pathways. In the MyD88-dependent pathway,
recruitment of the adaptor protein MyD88 leads to the production
of proinflammatory cytokines, such as TNF-a, through the
sequential activation of intracellular signaling molecules such as
IL-1R-associated kinase (IRAK1) and TNFR-associated factor 6
(TRAF6) [12,13]. Alternatively, in the MyD88 independent
pathway, recruitment of the adaptor molecule TIR domain-
containing adaptor-inducing IFN-b (TRIF) can result in the
production of type I interferons through the activation of IFN
regulatory factor 3 (IRF3) [14]. Signaling through the MyD88-
independent pathway can also induce TNF-a production, albeit in
a delayed manner, through activation of IRF3 [15]. With the
exception of TLR3 and TLR4, all TLRs signal exclusively
through the MyD88-dependent pathway. TLR3 is activated solely
through the MyD88-independent (TRIF) pathway and is essential
for anti-viral responses [14]. TLR4 is unique in that both MyD88-
dependent and independent pathways can become activated
following its ligation [16,17].
Full activation of TLR signals is essential for the elimination of
invading pathogens [18,19]. However, tight control of TLR
responses is critical as excessive TLR activation can result in
immunopathological conditions such as endotoxin shock and chronic
autoimmune disease [20]. As many of the mechanisms essential in
controlling TLR proinflammatory signals are still unclear, new
strategies to identify regulators of TLR signaling are needed.
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Short hairpin RNA (shRNA) mediated loss-of-function screens
in mammalian cells are powerful tools for the discovery of novel
gene functions. To date, two general strategies to develop shRNA
libraries have been described. The first requires the synthesis of
individual shRNAs targeting each gene of the genome [21,22].
Alternatively, several groups have generated shRNA libraries from
pools of double stranded cDNAs [23,24,25,26]. Both of these
strategies have been successfully used in large-scale mammalian
screens to identify novel gene functions in various biological
processes demonstrating the power of the shRNA library approach
[21,22,27,28,29,30,31]. However, these aforementioned RNAi
libraries have limited sequence diversity and are restricted to the
identification of known protein coding genes or highly expressed
cDNA populations. The generation of an RNAi library that is
random at the nucleotide level with unrestricted gene perturbation
potential could overcome the limitations of traditional RNAi
libraries.
We report the generation of a completely random shRNA
library and a novel reporter cell line for the efficient identification
of shRNAs with the desired phenotype. Using these tools, we
performed a large-scale genomic screen to identify shRNA
sequences which inhibit LPS-induced TNF-a production.
Results
Generation of a random shRNA library
The procedure for generating a completely random shRNA
library is outlined in Figure 1. First, a 120 bp oligonucleotide
containing 20 bp of the 39 end of U6 including a ‘‘G’’ to initiate
transcription, 18 random nucleotides (sense), and a stem-loop
structure that can act as a primer for synthesizing the strand
complementary to the random 18-bp (anti-sense) was made
(Fig. 1A). To stop DNA polymerization at the end of the anti-
sense 19-bp, a blocking primer containing the sequence comple-
mentary to the U6 promoter region was added to anneal to the U6
promoter in the extension reaction (Fig. 1B.1). Since T4 DNA
polymerase lacks strand displacement activity, the polymerase will
stop transcription upon reaching the 59 end of the blocking primer
(Fig. 1B.2). Following purification of the extended oligonucleotide
(Fig. 1B.3), we used terminal transferase (TdT) to attach a poly-
thymidine tract, which is recognized as a termination sequence by
RNA polymerase III, at the end of the oligonucleotide (Fig. 1B.4).
To make the oligonucleotide double stranded, we utilized Exo-
klenow fragment, which has strong strand displacement activity
and lacks exonuclease activity, and a poly-A oligonucleotide,
which can bind to the poly-thymidine tract of the oligonucleotide
(Fig. 1B.5). This purified double-stranded DNA was used as a
template and amplified using uracil containing primers (Fig. 1B.6).
Digestion of the PCR product with USER enzyme (Fig. 1B.7),
which digests uracil residues, was used to generate 7 and 4 base
pair overhangs to facilitate cloning (Fig. 1B.8). Following cloning
into the lentiviral vector pLL3.7, the extra sequence between the
random sense and antisense sequence was removed by BpmI
digestion and re-ligated, leaving a 9 base pair loop sequence [32].
Importantly, the entire procedure required only one PCR
amplification step, minimizing the possibility of sequence specific
bias in the generation of the library.
The average transformation efficiency was calculated to be
26108 colonies per ligation reaction. One hundred duplicate
electro-transformations were performed resulting in 261010 total
transformants. As the amount of starting oligonucleotide used was
in excess and sufficient to cover all possible random sequences, the
diversity of the library was estimated to be 261010 unique
sequences.
Figure 1. Schematic diagram of random shRNA library con-
struction. (A) Backbone of oligonucleotide used for generation of
shRNA library. (B.1–2) First, the 120 bp oligonucleotide containing 20 bp
of the 39 end of U6 including a ‘‘G’’ to initiate transcription, 18 random
nucleotides (sense) and a stem-loop structure that can act as a primer for
synthesizing the strand complementary to the random 18 bp (anti-sense)
was extended using T4 DNA polymerase in the presence of a blocking
primer which annealed to the U6 promoter region. (B.3–4) Following
purification of the extended oligonucleotide, a poly-thymidine tract was
added using terminal transferase (TdT). (B.5) Exo- klenow fragment was
used to make the oligonucleotide double stranded using a poly-A
oligonucleotide as a primer. (B.6) The purified double stranded DNA was
amplified using uracil containing primers. (B.7) The PCR product was
digested with USER enzyme to generate overhangs to facilitate cloning.
(B.8) The PCR fragment was cloned into the lentiviral vector pLL3.7, and
digested with BpmI to remove the extra sequence between the random
sense and antisense sequence, leaving a 9 base pair loop sequence.
doi:10.1371/journal.pone.0007029.g001
TLR shRNA Screen
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Sequencing results
After the library was constructed, 200 clones were randomly
sequenced. Among the 200 clones, 154 had the expected shRNA
sequence architecture (i.e., sense19-mer – loop – antisense 19-mer)
(data not shown). This result implies that about 77% of the library
contains the appropriate shRNA construct, indicating a functional
library size of approximately 1.561010. Among the incorrect
constructs, 22% contained sequences that lacked inverted repeats,
6% contained an incorrect loop sequence, and 2% lacked the poly-
T transcription termination sequence. Importantly, all 154 correct
sequences were unique, confirming the randomness of the shRNA
library.
Generation of TNF-DTA reporter cell line
To identify shRNAs which inhibit LPS induced proinflamma-
tory signals, we generated a murine macrophage reporter cell line
(RAW 264.7) that ectopically expresses the diphtheria toxin A
(DT-A) fragment driven by the murine TNF-a promoter (Fig. 2A).
Thus, cells transduced with an shRNA which inhibits genes
necessary for TLR-dependent proinflammatory signals would be
positively selected and survive, whereas cells transduced with an
irrelevant shRNA would express DT-A and die. Importantly, DT-
A cannot enter living cells in the absence of the DT-B fragment
[33]. As a result, expression of DT-A alone in cells transduced with
an irrelevant shRNA would not have bystander activity to
neighboring cells transduced with an shRNA that inhibits TNF-
a production (data not shown).
Due to the toxicity of DT-A, several safeguards were necessary
to prevent spontaneous cell death. First, wild type DT-A proved to
be too toxic as cells transfected with a TNF alpha reporter plasmid
driving wild type DT-A died spontaneously (data not shown).
Thus, we used the attenuated form of DT-A (Tox-176) which has
been shown to be 10–100 fold less active than the wild type DT-A
[34]. Second, the TNF-a promoter exhibits high basal levels of
gene expression (Fig. 3C). To obtain tight control of DT-A gene
expression, we modified the reporter plasmid to introduce two
TetO2 operator sites in the TNF-a promoter and used GFP
fluorescence as readout for TNF-a promoter activity (Fig. 3A).
Cotransfection of a plasmid encoding the Tet-repressor efficiently
suppressed the basal level of the TNF-a promoter activity by
three-fold (compare Fig. 3B vs. 3C). Importantly, Tet-repressor
mediated suppression of TNF-a promoter activity was reversible
by the addition of the inhibitor of Tet-repressor, doxycycline
(compare Fig. 3B vs. 3D).
Isolation of macrophage clones stably expressing both the
attenuated form of DT-A (Tox-176), under the control of a Tet-
repressor sensitive TNF-a promoter, and the Tet-repressor
(hereafter referred to as TNF-Tox cells) proved to be the most
efficient, as these clones were highly sensitive to LPS-induced
cytotoxicity and grew in vitro with kinetics similar to those of the
parental RAW 264.7 cells (data not shown).
To determine if downregulation of a known component of the
TLR signaling pathway would inhibit LPS-induced cytotoxicity,
we infected TNF-Tox cells with lentivirus expressing an shRNA
targeting MyD88, a critical adaptor molecule required for LPS-
dependent proinflammatory signals. Indeed, downregulation of
MyD88 in TNF-Tox reporter cells resulted in a 3-fold increase in
cell viability compared to mock infected cells (Fig. 2B). The
expression of a scrambled non-specific control shRNA sequence
did not result in an increase in cell viability, indicating that the
increased survival of MyD88 shRNA infected cells was a direct
result of MyD88 downregulation. Thus, the expression of an
shRNA targeting a molecule known to be essential for the
induction of LPS induced proinflammatory signals can protect the
TNF-Tox reporter cells from LPS-induced cytotoxicity, a proof-of-
principle that the reporter cell line is robust.
Large-scale shRNA screening
The random shRNA library was transduced into the TNF-Tox
reporter cell line at a concentration of virus chosen to ensure an
average of one copy of shRNA per cell. Seventy two hours post-
infection, the cells were stimulated with LPS and doxycycline and
monitored for survival. The genomic DNA from surviving cells
was harvested and PCR was used to amplify the enriched shRNA
sequences. Amplified DNAs were re-cloned into the lentiviral
vector and used to make fresh viral stocks containing the enriched
shRNA sequences. These sequences were subsequently transduced
Figure 2. Schematic of macrophage reporter cell line. (A)
Schematic of macrophage reporter cell line. The murine macrophage-
like cell line RAW 264.7 was stably co-transfected with the TNF-TetO2-
Tox176 reporter plasmid and the Tet-repressor expression plasmid,
PCDNA6/TR. A stable clone was isolated which exhibited the following
properties: upon stimulation with lipopolysaccharide and doxycycline,
cells expressed DT-A which resulted in cell death (top). However, when
transduced with shRNAs which inhibited LPS induced TNF-a produc-
tion, cells were resistant to LPS induced cytotoxicity (bottom). (B) RAW
264.7 mock infected (RAW), non-specific shRNA (control), and MyD88
specific shRNA infected TNF-Tox cells were stimulated with LPS (2 mg/
ml) and doxycycline (1 mg/ml) or just medium alone. Following forty
eight hours of stimulation, cell viability was measured using the MTS
assay. Percent viability reflects the Abs. 490 of stimulated cells divided
by the Abs. 490 of cells treated with medium alone times 100. Data are
representative of two independent experiments performed in triplicate.
N.S. = not significant, *** = p,0.001.
doi:10.1371/journal.pone.0007029.g002
TLR shRNA Screen
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into fresh TNF-Tox cells and the selection procedure was
repeated. Following five rounds of enrichment, we observed a
significant increase in cell survival compared to TNF-Tox cells
infected with a scrambled non-specific shRNA sequence (data not
shown). Again, PCR was used to amplify the shRNA sequences
from genomic DNA. The amplified DNAs were cloned into the
lentiviral vector and 140 clones were sequenced (Table 1).
Sequence analysis revealed that approximately half of the total
shRNAs sequenced were present at least twice, indicating a
significant enrichment as a result of the screening procedure
(Fig. 4A). Of particular interest, four shRNA sequences (HP-A,
HP-B, HP-C, and HP-D) were present at relatively high
frequencies and occurred 12, 10, 9, and 8 times, respectively, in
140 total clones (Fig. 4B). HP-A had a mismatch at position 9 of
Figure 3. Tet-repressor can reversible inhibit basal TNF-a promoter activity. (A) Schematic diagram of the TNF-TetO2-EGFP reporter
construct. Two Tet operator binding sites (TetO2) were cloned 10 bp downstream of the TNF-a promoter TATA box. (B–E) HEK-293T cells were
cotransfected with TNF-TetO2-EGFP reporter construct and (B and D) pcDNA6/TR which encodes the Tet-repressor driven by the CMV promoter
(CMV-TetR) or (C and E) pcDNA3.1 vector control (Vector) in the presence of doxycycline (DOX) or vehicle. EGFP expression was monitored 48 hours
later by flow cytometry.
doi:10.1371/journal.pone.0007029.g003
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Table 1. Sequence of 19-mer sense region of recovered shRNAs.
Name Sense sequence (59-.39) Name Sense sequence (59-.39) Name Sense sequence (59-.39)
T5-73 CAATCATCAGTGCTCCCCC T5-16 GAGCTAATCAGCATACAGT T5-4 GTAAATATACCTGTCGTAT
T5-76 GAAACGAGGTGCAATTTAC T5-44 GAGCTAATCAGCATACAGT T5-42 GTAAATATTTGAATGTTTA
T5-21 GAAATTATAGATACGGGGT T5-124 GAGGGAGATGGCAATTTTC T5-61 GTAACTCGTGGTGCGTATA
T5-86 GAAGTACGGTGGAGTATAG T5-24 GAGTACTACGTAAGGTATG T5-101 GTAAGTACGTTCCGTCAAC
T5-72 GAAGTGTCCGTATGTAATG T5-26 GAGTATTACGTAAGGTATG T5-121 GTACTAGGATTCGGGGTTC
T5-78 GAAGTTAATATGTGTTTTA T5-82 GAGTATTACGTCTTCTAGA T5-39 GTACTGCAGTTGCATACAG
T5-17 GAATAACGATCAGTTATAG T5-100 GATAATTTGGAAGTGCTTA T5-74 GTACTGCAGTTGCATACAG
T5-83 GAATAACGGTCAGTTATAG T5-117 GATAGATACAGCTCAAAAT T5-92 GTACTGCAGTTGCATACAG
T5-102 GAATACGTCATCAGGGTAG T5-133 GATAGATACAGCTCAAAAT T5-94 GTAGATCGCTCCACCCATG
T5-15 GAATAGAGTGCGTGAAGAC T5-109 GCATGATTGTCTCCTTGTT T5-37 GTAGGTAAGTGTCTCAATG
T5-126 GAATATTACGTAAGGTATG T5-111 GCCAATTACGTAGTTATGA T5-48 GTAGTATTGCTATTATGTC
T5-5 GAATATTACGTAAGGTATG T5-62 GATAGTTCCGCTTCTTTCG T5-122 GTAGTATTGCTATTATGTC
T5-9 GAATATTACGTAAGGTATG T5-96 GATCAGGAGTCACAAAGTC T5-134 GTAGTATTGCTATTATGTC
T5-47 GAATATTACGTAAGGTATG T5-128 GATCGCGTTCAGGTATTCA T5-123 GTAGTTGGCACATGTACAG
T5-49 GAATATTACGTAAGGTATG T5-104 GATTAGTGACTAGTCATCA T5-103 GTAGTTTTTTCGCTTCGCG
T5-52 GAATATTACGTAAGGTATG T5-120 GATTATCACCCCATGCCGT T5-18 GTTAGTTCTGTGTTCTCAG
T5-55 GAATATTACGTAAGGTATG T5-127 GATTATCACCCCATGCCGT T5-81 GTTAGTTCTGTGTTCTCAG
T5-84 GAATATTACGTAAGGTATG T5-97 GATTGCAGCCGTAGATTAG T5-140 GTTAGTTCTGTGTTCTCAG
T5-85 GAATATTACGTAAGGTATG T5-132 GCAAACGGGCTTCGCAAGA T5-22 GTCATTTTCGTGCTCAGCA
T5-99 GAATCTCAGTATTGCAGTT T5-64 GATAGTGCTACGGTATGTT T5-33 GTCGGATTTTAACAGTAAG
T5-10 GAATGGAAGTAATCGCGAT T5-80 GATAGTGCTACGGTATGTT T5-45 GTGACAGAAAACACATACT
T5-13 GAATGTATGCAGTCTCAAA T5-43 GCCGACGTCTTAGTTCAAT T5-46 GTGAGGTTGCATTATGTAT
T5-1 GAATGTATGCAGTCTCAAA T5-108 GCGGATCACTTCTTGTTCC T5-27 GTGATCTATGTATATTGTA
T5-23 GAATGTATGCAGTCTCAAA T5-25 GGACAAAGACAAGTTGTTA T5-41 GTGATCTATGTATATTGTA
T5-35 GAATGTATGCAGTCTCAAA T5-119 GGGAATTGTATTGAAGCTG T5-51 GTGATCTATGTATATTGTA
T5-40 GAATGTATGCAGTCTCAAA T5-34 GGGACGGCGTCCACGCTAT T5-53 GTGATCTATGTATATTGTA
T5-65 GAATGTATGCAGTCTCAAA T5-93 GGGGAGTAGCATATTTAGC T5-57 GTGATCTATGTATATTGTA
T5-68 GAATGTATGCAGTCTCAAA T5-7 GGGGGAGTGAGTGAATGAT T5-70 GTGATCTATGTATATTGTA
T5-136 GAATGTATGCAGTCTCAAA T5-125 GGGGGAGTGAGTGAATGAT T5-89 GTGATCTATGTATATTGTA
T5-110 GAATTGGGGTAAGTATGCT T5-12 GGGGGAGTGAGTGAATGAT T5-105 GTGATCTATGTATATTGTA
T5-6 GAATTGTCGTATGGACACT T5-50 GGGGGAGTGAGTGAATGAT T5-137 GTGATCTATGTATATTGTA
T5-19 GACAAGATCTTCATCCCAT T5-54 GGGGGAGTGAGTGAATGAT T5-131 GTGATCTATGTATATTGTA
T5-11 GACAAGGACTATGTGGGGG T5-69 GGGGGAGTGAGTGAATGAT T5-79 GTGATGATAGGATCAATCT
T5-28 GACAGATGGGAAGTAAGAA T5-71 GGGGGAGTGAGTGAATGAT T5-135 GTGATTCGTCCAAAAGCTT
T5-20 GACAGGAGTTGGAGTGTCT T5-75 GGGGGAGTGAGTGAATGAT T5-107 GTGGACTGAGGTGCTCAGG
T5-31 GACAGTATTGAAGCTGACT T5-87 GGGGGAGTGAGTGAATGAT T5-114 GTGGCGCAGAGTTACATGA
T5-129 GACATTAGTCTAGCAAATT T5-90 GGGGGAGTGAGTGAATGAT T5-58 GTTAATACGGATTCTCGAG
T5-29 GACATTAGTCTAGCAAATT T5-106 GGGGGAGTGAGTGAATGAT T5-130 GTTAATACGGATTCTCGAG
T5-8 GACCGAAATGTACGACCCC T5-139 GGGGGAGTGAGTGAATGAT T5-113 GTTAGCGCTCTATACTCGT
T5-115 GACGCGCATCGAGGGTAAG T5-36 GGTATATAGGACGAGAACG T5-67 GTATGATGATAGATATTGG
T5-77 GACGGACGTTTGTGTTGTA T5-66 GGTATGACTCAGTCCTCAG T5-98 GTATGATTGTCTCCTTGTT
T5-91 GACGGACGTTTGTGTTGTG T5-138 GGTAGAGGTACGCTTAGAA T5-32 GTCATGATTGGAAAGCTGT
T5-14 GAGAAAGGCCTGCGTCTCT T5-118 GGTAGAGGTACGCTTAGAA T5-59 GTTATGTGGACCAAAGCTT
T5-30 GAGAAAGGCCTGCGTCTCT T5-56 GGTGACCTTTCAGCGCAAA T5-88 GTTATGTGGACCAAAGCTT
T5-63 GAGAAAGGCCTGCGTCTCT T5-38 GGTGACCTTTCAGGGCAAA T5-95 GTTCGGGTGAAGCACCAGG
T5-2 GAGACAGCGTCATCTCAAA T5-112 GGTGTGTTAGTGTCTCAAG T5-3 GTTTATGTCGTATGTGTTC
T5-116 GAGACGGGACACATACGAG T5-60 GGTTGTATGCAGTCTCAAA
Bold letters indicate groups of replicate sequence.
doi:10.1371/journal.pone.0007029.t001
TLR shRNA Screen
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the sense strand with the antisense strand that corresponded to a
G:U wobble which has been shown to have no adverse effects on
RNAi activity [35]. Unexpectedly, we were unable to identify by
BLAST a single target transcript with perfect complementarity to
any of our recovered shRNA sequences.
Isolated shRNA sequences inhibit MyD88 dependent
TNF-a production in macrophages
To determine if these shRNA sequences targeted genes
necessary for the induction of proinflammatory cytokines, we
generated lentiviruses containing these hairpin sequences and
tested them individually in the TNF-Tox reporter cells. Following
LPS stimulation, all four shRNA sequences significantly inhibited
LPS-induced DT-A production as determined by increased
reporter cell viability (Fig. 5A). Interestingly, the extent of
increased viability appeared to correlate with the frequency of
the shRNAs in the sequenced pool. As HP-A and HP-B exhibited
the most dramatic increase in viability (2.2-fold and 2-fold
increase, respectively) over uninfected TNF-Tox cells, we focused
on these shRNA sequences for the remainder of our experiments.
To test if the recovered shRNA sequences also inhibited LPS-
induced TNF-a gene expression, HP-A and HP-B were trans-
duced into the parental macrophage-like cell line RAW 264.7.
Consistent with results from the TNF-Tox reporter cell, both HP-
A and HP-B significantly inhibited TNF-a gene expression in
RAW 264.7 cells compared to cells infected with a non-specific
shRNA sequence (Fig. 5B). The levels of inhibition (38% and 27%
for HP-A and HP-B, respectively) approached those seen in cells
infected with an shRNA targeting MyD88 (44%), suggesting that
both shRNAs targeted a gene (or genes) essential for LPS-induced
TNF-a production.
TLR4 is unique in that its activation can promote TNF-
production through both the MyD88-dependent pathway and the
MyD88-independent TRIF pathway [16,17]. As these signaling
pathways are also shared by other TLRs, we tested the ability of
our shRNA sequences to inhibit poly (I:C) (TLR3, MyD88
Figure 4. Analysis of sequences of enriched shRNA. (A) Pie chart
representing the frequency of shRNA occurrence among the 140 clones
sequenced. 2-3X refers to the pool of sequences represented two or
three times. Other refers to unique sequences. (B) Sequences of the
shRNAs present at the highest frequency. CACC represents the 39 end of
the human U6 promoter. TTCAAGAGA represents the loop sequence.
TTTTT represents the termination sequence. Number in parentheses
represents the frequency of occurrence out of 140 total sequences. The
underlined sequence represents a mismatch within the inverted repeat.
doi:10.1371/journal.pone.0007029.g004
Figure 5. Enriched shRNAs inhibit LPS induced TNF-a gene
expression. (A) RAW 264.7 mock infected (RAW), non-specific shRNA
(control), MyD88 specific shRNA (MyD88), and enriched shRNA (HP-A
and HP-B) infected TNF-Tox cells were stimulated with LPS (2 mg/ml)
and doxycycline (1 mg/ml) or just medium alone. Following forty eight
hours of stimulation, cell viability was measured using the MTS assay.
Percent viability reflects the Abs. 490 of stimulated cells divided by the
Abs. 490 of cells treated with medium alone times 100. Data are
representative of two independent experiments performed in triplicate.
(B) RAW 264.7 mock infected (RAW), non-specific shRNA (control), and
MyD88 specific shRNA (MyD88), and enriched shRNA (HP-A and HP-B)
infected RAW 264.7 cells were stimulated with LPS (2 mg/ml) or medium
alone for 4 hours and analyzed by QPCR. The relative quantities of TNF-
a mRNA per sample was calculated against GAPDH using the DDC(T)
formula, and normalized as fold change relative to RAW 264.7
incubated with medium alone. N.S. = not significant, *** = p,0.001,
** = p,0.01, * = p,0.05.
doi:10.1371/journal.pone.0007029.g005
TLR shRNA Screen
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independent) and Pam3Cys (TLR2, MyD88 dependent)-depen-
dent proinflammatory signals. Both HP-A and HP-B inhibited
Pam3Cys-dependent TNF-a production by 45% and 32%,
respectively (Fig. 6A). In contrast, neither of the two shRNAs
inhibited poly (I:C) dependent TNF-a production, suggesting that
the target (or targets) of these shRNAs was a component of the
MyD88-dependent pathway (Fig. 6B).
Discussion
Individual TLRs initiate distinct cellular responses. Yet the
mechanisms by which these specific signaling cascades are
activated remain unclear. The strong association between
dysregulation of TLR signaling and the development of chronic
inflammatory diseases [20] highlights the need for novel strategies
to identify molecular targets that modulate TLR-mediated
inflammatory pathways. Using an RNAi-based forward genetic
approach, we have identified unique shRNA sequences that
inhibit genes necessary for LPS (TLR4) and Pam3Cys (TLR2)-
dependent TNF-a production. Importantly, the inhibition of
proinflammatory cytokine production by these shRNAs appears to
be unique to MyD88-dependent signaling pathways as poly (I:C)
(TLR3)-dependent TNF-a production was not inhibited.
One of the hurdles in large-scale gene knockdown experiments
is the development of a robust screening system to identify
shRNAs with the intended effect. The need for a robust screening
system becomes increasingly important as the size of the shRNA
library increases, since the majority of shRNAs in a given shRNA
library pool will most likely not provide the desired phenotype.
Many RNA interference screens rely on the ability of an
interfering RNA to rescue a cell from death caused by some
cytotoxic drug. However, this approach is very limited as most
signaling pathways do not end with cell death. An alternative
approach is to use oligonucleotide microarrays to identify the
relative enrichment or depletion of individual shRNAs in a large
pool (barcode screening) [21,22]. By comparing the differences in
the ratio of shRNA populations in a control population versus a
population treated with a selective agent, shRNAs with altered
frequencies can be identified. This barcode screening approach
can be useful in identifying shRNA targets that are either positively
or negatively regulated. However, a major limitation to this system
is that the selective agent must provide a specific growth advantage
or disadvantage.
In the present study, we have developed a simple positive
selection approach for identifying essential components of
signaling pathways, such as TLR signaling, where ligand binding
does not alter cell viability. By placing DT-A production under the
control of the TNF-a promoter, we were able to positively select
shRNA sequences which inhibited LPS induced TNF-a produc-
tion. Positive selection results in the complexity of the shRNA
library pool decreasing significantly after each round of selection,
thereby increasing the likelihood of identifying shRNA sequences
that inhibit the targeted pathway. Importantly, this DT-A reporter
system can be modified for use with other promoter systems and
should greatly facilitate the identification of participants of various
signaling pathways.
RNAi was initially considered to be a sequence-specific gene
silencing mechanism that required a perfect match between the
guide strand of the siRNA and the mRNA target sequence [36].
Under this assumption, much effort has been expended attempting
to use RNAi to knockdown expression of specific genes. However,
more recently, the issue of specificity has been questioned as several
groups have demonstrated that various mismatches between the
guide strand of the siRNA and the mRNA target do not abolish the
silencing effect of the siRNA [37,38]. Additionally, microarray
analyses have demonstrated that siRNAs with only partial
complementarity to the 39 untranslated region of mRNAs can
cause reduction in the RNA levels of a large number of transcripts, a
phenomenon termed ‘‘off-target’’ effects [39,40]. Such ‘‘off-target’’
effects greatly increase the difficulty of identifying the genes actually
responsible for the selected phenotype.
Although verification of the siRNA target gene can be easily
done by generating multiple siRNAs targeting other regions of the
gene, this strategy becomes problematic if the phenotype caused
by the siRNA is mediated strictly by an ‘‘off-target’’ effect. A
recent example of this is a study by Lin et al. in which all of the top
candidate siRNAs from their siRNA screen were found to elicit
off-target gene silencing[41]. Through the use of gene expression
profiling and bioinformatic analysis, Lin et al. were able to identify
Mcl-1 as the ‘‘off-target’’ gene responsible for resistance to the
small molecule ABT-737 in their siRNA screen. Interestingly, the
library used in their study contained several siRNAs that were
Figure 6. Enriched shRNAs inhibit Pam3Cys but not poly (I:C)
dependent TNF-a gene expression. RAW 264.7 mock infected
(RAW), non-specific shRNA (control), and MyD88 specific shRNA
(MyD88), and enriched shRNA (HP-A and HP-B) infected RAW 264.7
cells were stimulated with (A) Pam3Cys (15 mg/ml), (B) Poly (I:C) (1 mg/
ml) or medium alone for 4 hours and analyzed by QPCR. The relative
quantities of TNF-a mRNA per sample was calculated against GAPDH
using the DDC(T) formula, and normalized as fold change relative to
RAW 264.7 incubated with medium alone. N.S. = not significant,
** = p,0.01, * = p,0.05.
doi:10.1371/journal.pone.0007029.g006
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designed to target Mcl-1. However, none of the four Mcl-1-specific
siRNAs from their library were able to sensitize cancer cells to
ABT-737 induced cytotoxicity, whereas the top candidate siRNAs
from their screen, specific for FGFR2, TNFRSF13B, and
PRDM13, were able to inhibit Mcl-1 gene expression through
partial complementarity of the siRNAs to the 39 untranslated
region of Mcl-1. Thus, caution needs to be taken when
interpreting data obtained from RNAi libraries as specific siRNAs
do not always target their intended gene and in some cases may
exhibit ‘‘off-target’’ effects.
Recently, it has been shown that overexpression of Argonaute-2
(Ago2) can enhance the specificity and potency of shRNAs for
mRNA targets with perfectly matched binding sites [42]. Thus, the
ectopic expression of Ago2 in our TNF-Tox cell line may increase
the likelihood of identifying perfectly matched shRNA sequences.
However, it should be noted that in the case of Lin et al.,
identification of Mcl-1 as a target for sensitizing cancer cells to
ABT-737 would not have been possible if siRNAs with partial
complementarity to Mcl-1 were not present to downregulate Mcl-
1 through ‘‘off-target’’ effects. Thus, shRNA libraries with greater
diversity, and potentially greater ‘‘off-target’’ gene silencing, such
as our random shRNA library, may provide greater genome wide
coverage and increase the probability of identifying small RNAs
capable of modulating complex cellular signaling pathways in a
phenotype driven screen. Although the bona fide targets of our
shRNA sequences could not be identified using target identifica-
tion algorithms such as BLAST, the recovered shRNA sequences
were confirmed to be potent inhibitors of MyD88-dependent
inflammation and may have therapeutic implications for the
treatment of chronic inflammatory disorders.
In summary, we have developed a completely random shRNA
library and a novel reporter cell line for large-scale genomic
screens. Importantly, any RNA species could potentially be
targeted using this shRNA library (for example, noncoding RNA
transcripts, alternatively spliced transcripts, or viral RNAs) in
virtually any mammalian cell. The use of such random shRNA
libraries for gene discovery coupled with stringent selection
systems can facilitate the rapid identification of small RNA
modulators involved in various biological processes.
Materials and Methods
Design of oligonucleotide for generation of random
shRNA library
An oligonucleotide containing 20 base pairs of the 39 end of the
U6 promoter (59-GGAAAGGACGAAACACC-39) followed by a
‘‘G,’’ the transcriptional start point of the human U6 promoter, 18
randomized oligonucleotides, a loop sequence (59-TTCAAGAGA-
39) [32], and extra sequences that form a hairpin structure that
contains a 32 base pair inverted repeat sequence with a TTCG loop
sequence (underlined) (59-TTCAAGAGATGCATAGCT CCA-
CATACTCCAGAATGACTTAATTCGTTAAGTCATTGTG-
GAGTATCTGGAGCTATGCATCTCTTGAA-39) was pur-
chased from IntegratedDNATechnologies (Coralville, IA) (Fig. 1A).
Generation of random shRNA library
The procedure for the production of the shRNA library is
shown schematically in Figure 1B.
Step 1
300 picomoles of the 120 base pair oligonucleotide was denatured
at 95uC for 10 minutes in 50 ml of NEB #2 restriction enzyme
buffer (New England Biolabs, Ipswitch, MA) and slowly cooled at a
rate of21uC/min to allow formation of the hairpin structure of the
oligonucleotide. Three nanomoles of U6 blocker primer (59-
GGTGTTTCGTCCTTTCC-39) complementary to the U6 se-
quence of the long oligonucleotide was also added to the mixture to
stop transcription by T4 DNA polymerase in the following step.
Step 2
The gap between the 39 end of the oligonucleotide and the 59
end of the U6 blocker was filled using T4 DNA polymerase (New
England Biolabs), which does not have strand displacement
activity, at 37uC for 30 minutes in the presence of 2 mM dNTP.
Step 3
To remove the short U6 blocker and purify the gap-filled
oligonucleotide, the reaction mixture from step B was resuspended
in 1x PAGE loading buffer (8 M urea, 0.04% bromophenol blue
(BPB), 0.04% xylene cyanol FF, 40 mM Tris pH 8.0, 0.001 mM
EDTA) and subjected to denaturating Urea PAGE. The DNA
band of the gap-filled oligonucleotide was excised from the gel and
purified.
Step 4
A poly-thymidine tail was added at the end of the gap-filled
oligonucleotide using terminal transferase (NEB) in the presence of
1 uM dTTP according to the manufacturer’s instruction. This
poly-T tail functions as a termination sequence for RNA
polymerase.
Step 5
The resulting oligonucleotide was purified using urea polyacryl-
amide gel electrophoresis and used as a template to generate double
stranded DNA using exonuclease deficient Klenow fragment (New
England Biolabs) and the primer, dsHP (AGCUATAGTT-
TAGCGGCCGCTTATACTACTCAAAAAAAAAAAAAAAAAA)
according the manufacturer’s instructions. Following agarose gel
electrophoresis the PCR fragment was gel purified using QIAquick
gel extraction kit (Qiagen, Valencia, CA) and resuspended in 60 ml of
water for use in the subsequent PCR amplification.
Step 6
Next the DNA was amplified using 1 ml of DNA template from step
5, 3 mM dNTP, 3 mM MgCl2, 1X PCR buffer, and 3 picomoles
of the uracil containing primers, HP-up primer (59-Biotin-TTTCGA/
deoxyU/TTCTTG GCTTTATATATCTTGTGGAAAGGACG-
AAACACC-39) and HP-lo primer (59-Biotin-GCC/deoxyU/ATAG-
TTTAGCGGCCGCTTATACTACTCAAAAAAAAAAAA AAA-
39) mixed with 2.5 units of Taq DNA polymerase (Invitrogen,
Carlsbad, CA). PCR was performed under the following conditions: 2
minutes at 95uC, 30 seconds at 50uC, and 30 seconds at 72uC. To
avoid formation of nonspecific bands, the optimal number of PCR
cycles was determined empirically.
Step 7
To generate cohesive ends, the amplified PCR product was
treated with the USER enzyme (New England Biolabs) according
to the manufacturer’s instructions, which specifically removes
deoxyuridine in the DNA. The final product contains unique 7 bp
and 4 bp overhangs at each end, which were used to facilitate
cloning into the lentiviral vector pLL3.7 (kindly provided by Dr.
Luk Van Parijs).
Step 8
Finally, samples were digested with BpmI to remove the extra
sequences between the inverted repeat sequences, blunt-ended and
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religated to generate the final product which contained the
following: the human U6 promoter including the ‘‘G’’ transcrip-
tion start site, a random 18-mer sequence, a TTCAAGAGA loop
sequence, the 19-mer sequences complementary to the random
sequence, followed by a poly-T termination sequence.
Cells and reagents
RAW 264.7 is a murine macrophage cell line, kindly provided by
Dr. Genhong Cheng (University of California Los Angeles, Los
Angeles, CA). RAW 264.7 cells were grown in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% calf serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Escherichia coli LPS (serotype O55:B5) and doxycycline were
obtained from Sigma (St. Louis, MO), polyinosinic:polycytidylic
acid (poly (I:C)) was obtained from Amersham Biosciences (Piscat-
away, NJ) and Pam3Cys was obtained from Alexis Biochemicals
(San Diego, CA). The following concentrations were used for
stimulation: poly (I:C) (TLR3, 1 mg/ml), LPS (TLR4, 2 mg/ml), and
Pam3Cys (TLR2, 15 mg/ml).
Plasmid constructs for reporter cell
The murine TNF-a promoter fragment was isolated from the
plasmid TNF-Luc [43], kindly provided by Dr. Peter Johnson
(National Cancer Institute, Frederick, MD), by digestion with
BamHI, blunt-ended by treatment with DNA polymerase I
(Klenow), and subsequently digested with HindIII. The resulting
TNF-a promoter fragment was inserted into the plasmid
pcDNA3.1 (Invitrogen) that had been digested with AccI, blunt-
ended by treatment with DNA polymerase I (Klenow), and
subsequently digested with HindIII to remove the CMV prompter.
The coding sequence of the wild-type diphtheria toxin A (DT-A)
catalytic fragment, the attenuated DT-A (Tox-176) with a G128D
mutation [34], or enhanced (E)GFP was isolated from the plasmids
pBK-CMV-DTA, pBK-CMV-Tox176 [44] [both kindly provided
by Dr. Ronald Rodriguez (Johns Hopkins University, Baltimore,
MD], or pEGFP-N1 (Clontech, Mountain View, CA), respective-
ly, and cloned downstream of the TNF-a promoter to generate the
reporter plasmids TNF-DTA, TNF-Tox176, and TNF-EGFP. A
Tet-On expression system was used to decrease the basal levels of
TNF-promoter induced gene expression. Two TetO2 sites were
inserted by PCR into each of the three reporter plasmids 10 bp
downstream of the TNF-promoter TATA box to generate TNF-
TetO2-DTA, TNF-TetO2-Tox176, and TNF-TetO2-EGFP.
Generation of macrophage reporter cells
RAW 264.7 cells (2.56106 cells) were plated overnight in a
60 mm dish. The following day, the cells were transfected with
16.5 mg of reporter plasmid using Superfect reagent (Qiagen)
according to the manufacturer’s instructions. Two days later, the
transfected cells were seeded in 96-well plates and selected for
stable expression by 2.5 mM histidinol (Sigma). Histidinol resistant
cells were cloned by limiting dilution and stimulated with LPS
(1 mg/ml) to assay for DT-A induced cytotoxicity or EGFP
fluorescence, as measured by CellTiter 96 AQueous (MTS)
solution (Promega, Madison, WI) or flow cytometry, respectively.
The generation of the tetracycline-inducible reporter plasmids
required two rounds of stable transfection. First, RAW 264.7 cells
were transfected with pcDNA6/TR (Invitrogen) using Superfect
transfection reagent, as above, and selected for stable expression
by G418 (1 mg/ml). Antibiotic resistant clones were assayed for
Tet-repressor expression by transfecting individual clones with
TNF-TetO2-EGFP and monitoring EGFP fluorescence by flow
cytometry. Clones with decreased EGFP fluorescence compared to
parental RAW 264.7 transfected cells were pooled and stably
transfected with the individual Tet-inducible reporter plasmids.
Histidinol (2.5 mM) resistant cells were cloned by limiting dilution
and assayed for DT-A induced cytotoxicity or EGFP fluorescence
as above in the presence or absence of doxycycline (1 mg/ml).
Generation of control shRNA-expressing lentiviral vectors
The viral backbone of our lentiviral expression constructs is
pLL3.7. PCR was performed to generate an shRNA expression
cassette containing the human U6 promoter, the specific shRNA
target sequence (containing the 19-mer sense sequence, the
TTCAAGAGA loop sequence, followed by the 19-mer antisense
sequence), followed by a poly-T termination sequence flanked by
the restriction sites XbaI and XhoI. The PCR fragment was
digested with XbaI and XhoI, and then inserted into the
unmodified pLL3.7. Primers 59-ATCGATTCTAGAAAGGTC-
GGGCAGGAAGAGGG-39 and 59-ATCGATCTCGAGAAAA-
ATTCTCCGAACGTGTCACGTCTCTTGAACGTGACAC-
GTTCGGAGAACGGTGTTTCGTCCTTTCCACAAG-39 were
used to generate a scrambled non-specific Control shRNA.
Primers 59-ATCGATTCTAGAAAGGTCGGGCAGGAAGAG-
GG-39 and 59-GATCTCGAGAAAAAGCCAGCGAGCTAAT-
TGAGAAACTCGAGTTTCTCAATTAGCTCGCTGGCCC-
GGTGTTTCGTCCTTTCCACAAG-39 were used to generate
the MyD88 specific shRNA.
Virus production
Lentiviruses were produced by cotransfecting HEK-293T cells
with the shRNA library lentivirus expression plasmid, the HIV-1
lentiviral packaging constructs pRSV-Rev and pMDLg/pRRE,
and the VSV-G expression plasmid pMD2G, kindly provided by
Dr. Didier Trono (University of Geneva Medical School, Geneva,
Switzerland), using the calcium phosphate transfection method.
Lentiviral supernatant was harvested at 48 and 72 hours post-
transfection, passed through a 0.45-mm filter, ultracentrifuged for
90 minutes at 19,400 rpm in a SW28 rotor, resuspended in 200 ml
of 10% CS in DMEM, and stored at 280uC until use. The
infectious titer was approximately 107 and 108 transducing units/
ml on RAW 264.7 cells and 293T cells, respectively, as determined
by flow cytometry.
Large-scale lentiviral shRNA screen
TNF-Tox reporter cells (1.56107 cells/dish) were seeded
overnight in 150 mm plates and transduced the following day
with sufficient lentiviral particles from our shRNA library to infect
80% of the cells as determined by flow cytometry. Following a
72 hour incubation, transduced cells were harvested, re-seeded
(1.56107 cells/dish) in 150 mm plates, and treated overnight with
doxycycline (1 mg/ml). The following day, cells were washed and
stimulated with 1 mg/ml LPS in the presence of doxycycline
(1 mg/ml) and incubated for 5–8 days to allow expansion of
surviving clones.
Recovery of shRNA sequences and reinfection
Genomic DNA from surviving cells was isolated using Qiagen
DNeasy kit (Qiagen). PCR amplification of the shRNA inserts was
performed with Platinum Taq DNA polymerase (Invitrogen) using
the following primers: 59-ATCGATTCTAGAAAGGTCGGG-
CAGGAAGAGGG-39 and 59-ATGCATGGCGGTAATACG-
GTTATCC-39. The PCR fragment was digested with XbaI and
XhoI, and then inserted into the unmodified pLL3.7 lentivirus
vector. Generation of lentivirus and screening was performed as
described above. After five rounds of enrichment, PCR amplified
shRNA inserts were subcloned into the pLL3.7 lentivirus vector
TLR shRNA Screen
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and individual clones sequenced to determine the shRNA
sequence.
RNA isolation and quantitative PCR (QPCR) analysis
RNA was isolated from RAW 264.7 cells using TRIzol Reagent
(Invitrogen), and cDNA was synthesized using the SuperScript III
First-Strand Synthesis SuperMix (Invitrogen). SYBR Green
reactions were conducted with the IQ SYBR Green mix (Bio-
Rad, Hercules, CA). Reactions were run on the MJR Opticon
Continuous Fluorescence detector (Bio-Rad) and analyzed with
Opticon Monitor Software 1.08 (Bio-Rad). The relative quantities
of the gene tested per sample were calculated against GAPDH
using the DDC(T) formula. The following primers were used:
TNF-up – 59-ATGAGCACAGAAAGCATGATC-39; TNF-down
– 59-TACAGGCTTGTCACTCGAATT-39; GAPDH-up – 59
GTTGCCATCAATGACCCCTTCATTG-39; GAPDH-down –
59-GCTTCACCACCTTCTTGATGTCATC-39.
Acknowledgments
Flow cytometry was performed in the UCLA Jonsson Comprehensive
Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry
Core Facility.
Author Contributions
Conceived and designed the experiments: JC YCK SLM. Performed the
experiments: JC YCK. Analyzed the data: JC YCK SLM. Contributed
reagents/materials/analysis tools: JC YCK. Wrote the paper: JC YCK SLM.
References
1. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:
499–511.
2. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev
Immunol 20: 197–216.
3. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. (1998) Defective
LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Science 282: 2085–2088.
4. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, et al. (1999)
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp
Med 189: 615–625.
5. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. (1999) Cutting
edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to
lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol
162: 3749–3752.
6. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999)
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-
like receptor 2. J Biol Chem 274: 17406–17409.
7. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, et al. (1999) Differential
roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive
bacterial cell wall components. Immunity 11: 443–451.
8. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, et al. (1999) Cell
activation and apoptosis by bacterial lipoproteins through toll-like receptor-2.
Science 285: 736–739.
9. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, et al. (1999) Host
defense mechanisms triggered by microbial lipoproteins through toll-like
receptors. Science 285: 732–736.
10. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, et al. (2000) Cutting
edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide
macrophage-activating lipopeptide-2 activates immune cells through a toll-like
receptor 2- and MyD88-dependent signaling pathway. J Immunol 164:
554–557.
11. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of
double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
Nature 413: 732–738.
12. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, et al. (1998)
MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling
pathways. Mol Cell 2: 253–258.
13. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A (1998) The human toll
signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK
activation upstream of tumor necrosis factor receptor-associated factor 6
(TRAF6). J Exp Med 187: 2097–2101.
14. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. (2003) Role of
adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
Science 301: 640–643.
15. Covert MW, Leung TH, Gaston JE, Baltimore D (2005) Achieving stability of
lipopolysaccharide-induced NF-kappaB activation. Science 309: 1854–1857.
16. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of
Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:
743–748.
17. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S (1999) Unresponsiveness of
MyD88-deficient mice to endotoxin. Immunity 11: 115–122.
18. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking
innate and acquired immunity. Nat Immunol 2: 675–680.
19. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol
1: 135–145.
20. Cook DN, Pisetsky DS, Schwartz DA (2004) Toll-like receptors in the
pathogenesis of human disease. Nat Immunol 5: 975–979.
21. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, et al. (2004)
A large-scale RNAi screen in human cells identifies new components of the p53
pathway. Nature 428: 431–437.
22. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, et al. (2004) A resource
for large-scale RNA-interference-based screens in mammals. Nature 428:
427–431.
23. Du C, Ge B, Liu Z, Fu K, Chan WC, et al. (2006) PCR-based generation of
shRNA libraries from cDNAs. BMC Biotechnol 6: 28.
24. Luo B, Heard AD, Lodish HF (2004) Small interfering RNA production by
enzymatic engineering of DNA (SPEED). Proc Natl Acad Sci U S A 101:
5494–5499.
25. Sen G, Wehrman TS, Myers JW, Blau HM (2004) Restriction enzyme-
generated siRNA (REGS) vectors and libraries. Nat Genet 36: 183–189.
26. Shirane D, Sugao K, Namiki S, Tanabe M, Iino M, et al. (2004) Enzymatic
production of RNAi libraries from cDNAs. Nat Genet 36: 190–196.
27. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, et al. (2007) A genome-
wide transgenic RNAi library for conditional gene inactivation in Drosophila.
Nature 448: 151–156.
28. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, et al. (2008) Identification of
RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451:
335–339.
29. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, et al. (2006) A
lentiviral RNAi library for human and mouse genes applied to an arrayed viral
high-content screen. Cell 124: 1283–1298.
30. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, et al. (2006) A loss-of-function
RNA interference screen for molecular targets in cancer. Nature 441: 106–110.
31. Silva JM, Li MZ, Chang K, Ge W, Golding MC, et al. (2005) Second-generation
shRNA libraries covering the mouse and human genomes. Nat Genet 37:
1281–1288.
32. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression
of short interfering RNAs in mammalian cells. Science 296: 550–553.
33. Pappenheimer AM Jr (1977) Diphtheria toxin. Annu Rev Biochem 46: 69–94.
34. Maxwell F, Maxwell IH, Glode LM (1987) Cloning, sequence determination,
and expression in transfected cells of the coding sequence for the tox 176
attenuated diphtheria toxin A chain. Mol Cell Biol 7: 1576–1579.
35. Akashi H, Miyagishi M, Yokota T, Watanabe T, Hino T, et al. (2005) Escape
from the interferon response associated with RNA interference using vectors that
encode long modified hairpin-RNA. Mol Biosyst 1: 382–390.
36. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001)
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila
melanogaster embryo lysate. Embo J 20: 6877–6888.
37. Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations
and chemical modifications in a siRNA. Nucleic Acids Res 31: 589–595.
38. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H (2002) Positional
effects of short interfering RNAs targeting the human coagulation trigger Tissue
Factor. Nucleic Acids Res 30: 1757–1766.
39. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. (2003)
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol
21: 635–637.
40. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, et al. (2006)
Widespread siRNA ‘‘off-target’’ transcript silencing mediated by seed region
sequence complementarity. Rna 12: 1179–1187.
41. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, et al. (2007) ‘Seed’
analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the
small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972–3979.
42. Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, et al. (2008)
Coexpression of Argonaute-2 enhances RNA interference toward perfect match
binding sites. Proc Natl Acad Sci U S A 105: 9284–9289.
43. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, et al. (1998) Tumor
necrosis factor alpha transcription in macrophages is attenuated by an autocrine
factor that preferentially induces NF-kappaB p50. Mol Cell Biol 18: 5678–5689.
44. Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, et al. (2002) Prostate-
specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility
and specificity of expression of prostate-specific antigen promoter-driven DT-A
adenoviral-mediated gene transfer. Cancer Res 62: 2576–2582.
TLR shRNA Screen
PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7029
